ARGAN INC

AGX

Held by 1 specialist biotech fund

Fund Holdings

AI Signal

# Signal Note: Driehaus initiates AGX position Driehaus' $7.5M entry into Argan suggests conviction in the company's core asset, topical retinoid AGX-51 for acne, which is in Phase 2b development.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 23,830Value: $7.5M

# Signal Note: Driehaus initiates AGX position Driehaus' $7.5M entry into Argan suggests conviction in the company's core asset, topical retinoid AGX-51 for acne, which is in Phase 2b development. The position timing may reflect anticipated clinical readout or upcoming catalysts in dermatology, a segment where Driehaus has demonstrated selective interest despite limited biotech overlap with growth equities.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN1 fund WLDN1 fund LASR1 fund ONTO1 fund VALE1 fund TNDM1 fund TKO1 fund TNL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: